Use in pregnancy

Lumeva · Episodic migraine

MI-2026-0551RoutineClosedWithin SLASafety

FAFatima Al-SayedMedical Information Lead

Restricted — potential adverse event

Access limited to Medical Information and Safety roles. Details are captured minimally and routed to pharmacovigilance per SOP-PV-014. AI features are disabled for this record (PRD §27.7).

Received: 31 Mar 2026, 09:19 UTC
Channel: Web portal
Requestor type: HCP
Country / region / team: Brazil · Latin America · MI APAC
Category: Safety
Response type: Standard response
Owner: FAFatima Al-Sayed
Due: 05 Apr 2026, 09:19 UTC
Responded: 01 Apr 2026, 22:19 UTC
Quality review: Not required
Related insight: —
Related standard response: SR-LMV-009 · Use in pregnancy and lactation (v2)

Workflow

12-stage inquiry workflow (PRD §16). Advancing records an audit event.

Received
Triage
Assigned
In progress
Escalated
Draft response
Medical review
Quality review
Sent
Follow-up required
11Closed
12Archived

Current stageClosedDemo action — not persisted

SLA

Routine: 120 h target · Routine 120 h / Urgent 48 h / Critical 24 h

SLA hours

120

Elapsed

37 h

to response

Remaining

83 h

31%

Timeline

01 Apr 2026, 22:19 UTC
Response sent
Standard response · quality review not required
05 Apr 2026, 09:19 UTC
SLA due (120 h)
31 Mar 2026, 09:19 UTC
Received via Web portal
HCP · Brazil
31 Mar 2026, 09:19 UTC
Triage and assignment
Urgency Routine · assigned to MI APAC

Draft response

Restricted record

AI suggestion disabled — safety-flagged inquiries are not interpreted by AI (PRD §27.7).

Draft response

Audit history

No audit events for this record

Create, update, approve and export events appear here with user, timestamp, previous and new values.

Data lineage: MI inquiry platform (IRMS, INT-05) · received 31 Mar 2026 · hourly sync.